The Pharmacogenomics Opportunity in the Precision Genomic Testing Market
Description: Focusing on the specific sub-segment of pharmacogenomics (PGx) and its role in improving drug efficacy and reducing adverse drug reactions through genetic testing.
A significant opportunity within the Precision Genomic Testing Market lies in Pharmacogenomics (PGx). PGx is the study of how an individual’s genes affect their response to drugs. By analyzing specific genetic markers, PGx testing allows clinicians to predict whether a patient will respond positively to a medication, require a lower or higher dose, or be at risk for a serious adverse drug reaction.
The growing adoption of PGx is being driven by the need to improve therapeutic efficacy and patient safety across various medical fields, including oncology, psychiatry, and cardiology. This genomic-guided prescribing reduces the costly and time-consuming "trial-and-error" method of dosing, leading to better patient outcomes and lower overall healthcare costs in the long run.
As regulatory bodies…